Hepatocellular carcinoma

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

Researchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…

This study tests different combinations of chemotherapy drugs, along with surgery, for children and young adults with two types of liver cancer: hepatoblastoma and hepatocellular carcinoma. The goal is to see which combinations work best to stop tumor growth and improve survival.…

This phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…

This pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one …

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a…

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This phase II trial tests whether lisinopril, a widely used blood pressure medication, can prevent liver damage from getting worse in people with non-alcoholic fatty liver disease (NAFLD). The study enrolls 45 adults with advanced liver scarring and measures changes in fibrosis m…

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…

This study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…

This trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This trial is testing whether a combination of chemotherapy, immunotherapy, and a targeted therapy can help people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. Participants receive a regimen of two chemotherapy drugs (oxa…

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This trial is testing whether combining two types of radiation therapy can safely treat liver cancer that cannot be removed with surgery. The approach uses Y-90 microspheres delivered directly to the liver, followed by targeted external radiation (SBRT). The study also uses PET-C…

This phase 3 trial tests whether the immunotherapy drug nivolumab can prevent liver cancer from coming back in people who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. The…

This phase 3 study tests whether adding nofazinlimab (an immunotherapy) to lenvatinib (a standard targeted therapy) helps people with advanced liver cancer live longer. About 534 participants who have not had prior systemic treatment will receive either the combo or a placebo plu…

This trial is testing whether giving a combination of drugs before surgery can reduce the risk of liver cancer returning in patients with a single, early-stage tumor that has a high chance of recurrence. Participants will receive either chemotherapy directly into the liver or a t…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not cand…

This early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive t…

This Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …

This trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase 2 trial tests whether combining the targeted drug regorafenib with the immunotherapy durvalumab can shrink high-risk liver cancer before surgery. The study enrolled 4 adults with stage IB to IIIA hepatocellular carcinoma. Researchers are measuring how many patients see…

This study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). …

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and…

This phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This Phase 3 trial tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 participants will receive either the combination or a placebo plus lenvatinib. The study is double…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) before and after a standard tumor-burning procedure (radiofrequency ablation) can prevent small liver cancers from returning. About 202 adults with early-stage liver cancer will be randomly ass…

This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …

This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…

This study tests whether combining the drug regorafenib with a targeted radiation treatment (Y-90 radioembolization) can control liver cancer that cannot be removed by surgery. About 30 adults with this type of liver cancer will receive the combination therapy. The main goals are…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the …

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…

This study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…

This phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …

This early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…

This early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…

This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…

This early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…

This study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…

This study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This study is testing a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The microspheres are tiny glass beads containing radioactive yttrium-90, which are injected into the liver's blood vessels to deliver radiation directly to …

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…

This phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…

This phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This was a planned Phase 1 study to test NP-101, a drug made from black seed, in people with liver cancer that cannot be removed by surgery. Participants would have taken NP-101 daily for 28 days before receiving standard Y-90 radiation treatment. The goal was to find the safest …

This study aimed to test a new experimental drug called BC3402 combined with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The trial was withdrawn before any participants were enrolled, so no data on…

This early-stage trial is testing a combination of two drugs—cadonilimab and regorafenib—in 30 adults with advanced liver cancer that has worsened after at least one prior therapy. The goal is to see if the combo can shrink tumors or slow the disease, while also checking for side…

This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…

This study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…

This study tests whether the drug everolimus can lower the risk of liver cancer coming back after a liver transplant in patients with high-risk hepatocellular carcinoma. About 336 adults who have just received a transplant will be randomly assigned to take everolimus plus tacroli…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This pilot trial is testing whether adding stereotactic body radiation therapy (SBRT) to the standard transarterial chemoembolization (TACE) can better control liver cancer in patients waiting for a liver transplant. About 40 patients will be enrolled to see if the combination im…

This study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…

This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This trial tests a device called HistoSonics that uses focused ultrasound (sound waves) to mechanically destroy liver tumors without heat or needles. It includes 24 adults with liver cancer or tumors that spread to the liver. The main goals are to see if the device can fully cove…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This study tests whether icaritin soft capsules, taken daily for up to a year, can help prevent liver cancer from coming back in patients who had surgery to remove their tumor. Twenty adults with high-risk features for recurrence will take the capsules twice a day. The main goal …

This study tests whether simvastatin, a drug typically used for cholesterol, can reduce the risk of liver complications in veterans with compensated cirrhosis (scarred but symptom-free liver). About 142 participants will take either simvastatin or a placebo nightly for several ye…

This phase 3 trial tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—can prevent liver cancer from coming back in patients at high risk of recurrence after curative surgery or ablation. About 687 participants will receive eithe…

This phase 3 trial is testing whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab helps people with advanced liver cancer that cannot be surgically removed. About 687 participants will receive either the three-drug combo or the two-drug combo pl…

This study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive eithe…

This early-phase trial tests a cancer vaccine (IMA970A) combined with an immunotherapy drug (durvalumab) in 10 patients with early- to intermediate-stage liver cancer who have already received standard treatments. The goal is to see if the combination is safe and can help reduce …

This study tests a new, non-invasive treatment called histotripsy that uses high-intensity ultrasound waves to destroy liver tumours. It works by creating tiny bubbles in the tumour that burst and break it apart, while sparing healthy tissue. The trial will enroll 60 people with …

This study looks at how well a treatment called 90Y radioembolization works for people with early-stage liver cancer. Researchers will track 200 patients in Korea to see how the tumors respond, how long patients live, and any side effects. The goal is to gather real-world data to…

This phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …

This phase 3 trial tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their disease getting worse. About 423 participants are randomly assigned to get either the co…

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-phase study tests a new treatment for advanced liver cancer. Participants will receive focused radiation to the tumor along with two immunotherapy drugs (tremelimumab and durvalumab) to help the immune system fight the cancer. The goal is to see if this combination is …

This trial tests a device called HistoSonics that uses focused ultrasound waves to mechanically destroy liver tumors without heat, needles, or incisions. About 47 adults with liver cancer or tumors that spread to the liver will receive this treatment. The main goals are to see if…

This study looks at whether a three-part treatment—blocking the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that boost the immune system—can help people with intermediate to advanced liver cancer that cannot be removed by surgery. The 17 participants all rece…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This study tests an immunotherapy called AlloStim against standard treatments (sorafenib, lenvatinib, or chemotherapy) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. Participants are randomly assigned to receive either AlloS…

This study tests a treatment called irreversible electroporation (IRE) for people with liver cancer who cannot have surgery because their tumors are too close to major blood vessels. IRE uses short, strong electrical pulses to destroy cancer cells without harming nearby blood ves…

This study tests whether giving a short course of targeted radiation (SBRT) along with two immunotherapy drugs (atezolizumab and bevacizumab) before surgery is safe and effective for people with liver cancer that can be removed. About 20 participants will receive this combination…

This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo or radiation works for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and Asia will be include…

This early-phase study tests a new cell therapy called CT0180 in 21 adults with advanced liver cancer that has not responded to other treatments. The main goals are to check safety, find the best dose, and see how long the cells stay in the body. Participants receive one or more …

This early-phase study tests a new RNA-based drug (MTL-CEBPA) together with two approved immunotherapy drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who have not had prior systemic treatment. The main goals are to find the safest dose and to see how th…

This early-phase trial is testing a combination of an experimental drug (JS014), an immunotherapy (toripalimab), and a targeted chemotherapy procedure (TACE) in 20 people with advanced liver cancer that cannot be surgically removed. The main goal is to check safety, but researche…

This early-phase trial is testing an experimental drug called BI-1910, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have worsened after standard treatments. The main goals are to see if the drug is saf…

This early-phase trial tests a new experimental treatment called GAP T cells in children and young adults with liver cancer that has come back or not responded to standard therapy. The cells are made from the patient's own immune T cells, which are genetically modified to recogni…

This study tests whether a supervised exercise program before and after liver transplant can help patients recover faster and have fewer complications. Sixty adults awaiting a liver transplant will take part. The program includes aerobic, muscle, and balance exercises for 8 weeks…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…

Researchers are testing a blood test panel called Glycotest HCC to see if it detects early-stage liver cancer better than the standard alpha-fetoprotein (AFP) test. The study includes 766 people with cirrhosis, some of whom have early liver cancer and some who do not. Participant…

This early-phase study is testing whether a special PET scan using a drug called PYLARIFY can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will compare the results to stan…

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combinatio…

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…

This study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard u…

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…

This study is testing a new blood test called Oncoguard Liver to see how well it detects liver cancer (hepatocellular carcinoma) in people at increased risk, such as those with cirrhosis or hepatitis B. About 3,000 participants will provide a blood sample and undergo imaging like…

This study compares a shortened MRI scan to the standard ultrasound for detecting liver cancer in 820 adults with liver cirrhosis. Researchers will also check if blood markers can help spot cancer early. The goal is to see if the faster MRI is more accurate and cost-effective for…

This phase 2 trial tests whether a vaccine made from a patient's own dendritic cells — immune cells trained to recognize liver cancer — can prevent the cancer from returning after surgical removal of the tumor. About 74 adults with a high risk of recurrence will receive the vacci…

Researchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for…

This early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study explores why some people with fatty liver disease progress to severe liver damage and cancer. Researchers will analyze genetic data from over 35,000 patients and use lab-grown liver organoids to study fat droplets in liver cells. The goal is to identify genetic markers…

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut b…

This study follows 2,002 people at high risk for liver cancer to find better ways to detect it early. Researchers are testing a panel of blood-based miRNA markers, gut microbiome changes, and MRI-based AI algorithms to predict who develops the disease. The goal is to improve on c…

This study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compar…

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …

This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …

This study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…

This study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…

This study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…

This study follows 10,000 adults with hepatocellular carcinoma (a type of liver cancer) to see how the disease changes over time and how different treatments affect patients in real life. Researchers are collecting information from regular doctor visits and patient surveys, and b…

This study is screening 1,000 patients at the HOPE clinic in Houston for liver fibrosis and cirrhosis using surveys, blood tests, and a non-invasive liver scan called FibroScan. The goal is to find early signs of liver damage that could lead to cancer, so that prevention or early…

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …

This study tests whether an automatic reminder in the electronic health record can increase the number of cirrhosis patients who get screened for liver cancer (hepatocellular carcinoma). The reminder prompts doctors to order a liver ultrasound when they see a patient with cirrhos…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…

This study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary l…

This study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool…

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…

This study looked back at medical records from 800 patients with unresectable liver cancer who were treated with lenvatinib-based therapy at six hospitals. Researchers analyzed how long patients survived, how well the cancer responded, and any side effects. The goal is to better …

This study looks at people with liver cancer that was too large or spread out to remove with surgery, but then completely disappeared after drug treatment. Researchers want to see if having surgery after the drugs work helps people live longer compared to just watching and waitin…

This study looks at whether a home-based exercise program is practical and safe for people aged 65 and older who are waiting for liver or bile duct cancer surgery. About 25 participants will do supervised exercise sessions and be tracked for how many join, stick with it, and repo…

This pilot study aims to develop new ways to diagnose colon cancer and predict if it will spread to the liver. Researchers will collect blood and liver tissue samples from 51 patients undergoing surgery for colon cancer or benign colon growths. The goal is to find biomarkers that…

This study looks at how liver stiffness (hardness) affects treatment results in people with liver cancer. About 207 patients will be followed to see if stiffness predicts survival and treatment side effects. The goal is to help doctors choose the best therapy for each patient.

This study looks back at the medical records of 2,500 liver cancer patients treated at a major hospital in Taiwan between 2019 and 2024. It focuses on people who received newer drugs like immunotherapy and targeted therapy instead of the older standard treatment. The goal is to s…

This study is collecting blood and tissue samples from 360 people with early-stage liver cancer who have had surgery to remove their tumors. Researchers want to find biological markers that could predict if the cancer will come back. The goal is to better understand the immune sy…